- Home
- FLG vs SRRK Comparison
FLG vs SRRK Comparison
Compare FLG & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLG
- SRRK
- Stock Information
- Founded
- FLG 1859
- SRRK 2012
- Country
- FLG United States
- SRRK United States
- Employees
- FLG N/A
- SRRK N/A
- Industry
- FLG
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLG
- SRRK Health Care
- Exchange
- FLG NYSE
- SRRK Nasdaq
- Market Cap
- FLG 4.6B
- SRRK 4.2B
- IPO Year
- FLG 1993
- SRRK 2018
- Fundamental
- Price
- FLG $12.20
- SRRK $37.70
- Analyst Decision
- FLG Hold
- SRRK Strong Buy
- Analyst Count
- FLG 4
- SRRK 7
- Target Price
- FLG $12.50
- SRRK $40.43
- AVG Volume (30 Days)
- FLG 7.7M
- SRRK 793.4K
- Earning Date
- FLG 01-30-2025
- SRRK 02-27-2025
- Dividend Yield
- FLG 0.33%
- SRRK N/A
- EPS Growth
- FLG N/A
- SRRK N/A
- EPS
- FLG N/A
- SRRK N/A
- Revenue
- FLG $1,618,000,000.00
- SRRK N/A
- Revenue This Year
- FLG N/A
- SRRK N/A
- Revenue Next Year
- FLG $21.97
- SRRK N/A
- P/E Ratio
- FLG N/A
- SRRK N/A
- Revenue Growth
- FLG N/A
- SRRK N/A
- 52 Week Low
- FLG $5.10
- SRRK $6.76
- 52 Week High
- FLG $14.43
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- FLG N/A
- SRRK 41.93
- Support Level
- FLG N/A
- SRRK $35.35
- Resistance Level
- FLG N/A
- SRRK $38.61
- Average True Range (ATR)
- FLG 0.00
- SRRK 1.80
- MACD
- FLG 0.00
- SRRK -0.16
- Stochastic Oscillator
- FLG 0.00
- SRRK 34.20
About FLG FLAGSTAR FINANCIAL INC
Flagstar Financial Inc operates over 400 branches, including a presence in the Northeast and Midwest and locations in high-growth markets in the Southeast and West Coast. In addition, the Bank has approximately 90 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high net-worth individuals and their businesses.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.